|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
46,110,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile BioAtla is a biopharmaceutical company engaged in developing specific and selective antibody-based therapeutics for the treatment of various cancers. Co.'s lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. Co. also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
81,495 |
83,495 |
252,735 |
Total Buy Value |
$0 |
$172,540 |
$177,620 |
$814,041 |
Total People Bought |
0 |
4 |
4 |
4 |
Total Buy Transactions |
0 |
4 |
5 |
15 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Short Jay M Phd |
Chief Executive Officer |
|
2022-11-30 |
4 |
D |
$11.01 |
$51,384 |
D/D |
(4,667) |
1,382,659 |
|
- |
|
Mcbrinn Sylvia |
Director |
|
2022-11-22 |
4 |
B |
$8.27 |
$16,540 |
D/D |
2,000 |
5,425 |
2.39 |
- |
|
Sievers Eric |
Chief Medical Officer |
|
2022-10-31 |
4 |
D |
$6.89 |
$3,817 |
D/D |
(554) |
85,063 |
|
- |
|
Waldron Richard A |
Chief Financial Officer |
|
2022-10-31 |
4 |
D |
$6.89 |
$6,683 |
D/D |
(970) |
123,714 |
|
- |
|
Smith Scott Andrew |
President |
|
2022-10-31 |
4 |
D |
$6.89 |
$12,340 |
D/D |
(1,791) |
324,462 |
|
- |
|
Short Jay M Phd |
Chief Executive Officer |
|
2022-10-31 |
4 |
D |
$6.89 |
$23,798 |
D/D |
(3,454) |
1,387,326 |
|
- |
|
Vasquez Christian |
See Remarks |
|
2022-10-31 |
4 |
D |
$6.89 |
$1,337 |
D/D |
(194) |
73,555 |
|
- |
|
Sievers Eric |
Chief Medical Officer |
|
2022-09-30 |
4 |
D |
$7.70 |
$4,274 |
D/D |
(555) |
85,617 |
|
- |
|
Waldron Richard A |
Chief Financial Officer |
|
2022-09-30 |
4 |
D |
$7.70 |
$7,469 |
D/D |
(970) |
124,684 |
|
- |
|
Vasquez Christian |
See Remarks |
|
2022-09-30 |
4 |
D |
$7.70 |
$1,494 |
D/D |
(194) |
73,749 |
|
- |
|
Short Jay M Phd |
Chief Executive Officer |
|
2022-09-30 |
4 |
D |
$7.70 |
$22,238 |
D/D |
(2,888) |
1,390,780 |
|
- |
|
Smith Scott Andrew |
President |
|
2022-09-30 |
4 |
D |
$7.70 |
$13,791 |
D/D |
(1,791) |
326,253 |
|
- |
|
Mcbrinn Sylvia |
Director |
|
2022-09-13 |
4 |
B |
$8.20 |
$8,200 |
D/D |
1,000 |
3,000 |
2.39 |
- |
|
Mcbrinn Sylvia |
Director |
|
2022-09-12 |
4 |
B |
$8.85 |
$17,700 |
D/D |
2,000 |
2,000 |
2.39 |
- |
|
Sievers Eric |
Chief Medical Officer |
|
2022-08-31 |
4 |
D |
$8.71 |
$4,834 |
D/D |
(555) |
86,172 |
|
- |
|
Waldron Richard A |
Chief Financial Officer |
|
2022-08-31 |
4 |
D |
$8.71 |
$8,449 |
D/D |
(970) |
125,654 |
|
- |
|
Smith Scott Andrew |
President |
|
2022-08-31 |
4 |
D |
$8.71 |
$15,600 |
D/D |
(1,791) |
328,044 |
|
- |
|
Vasquez Christian |
See Remarks |
|
2022-08-31 |
4 |
D |
$8.71 |
$1,690 |
D/D |
(194) |
73,943 |
|
- |
|
Short Jay M Phd |
Chief Executive Officer |
|
2022-08-31 |
4 |
D |
$8.71 |
$25,154 |
D/D |
(2,888) |
1,393,668 |
|
- |
|
Short Jay M Phd |
Chief Executive Officer |
|
2022-08-12 |
4 |
B |
$7.84 |
$206,600 |
D/D |
26,350 |
1,396,556 |
3.23 |
- |
|
Short Jay M Phd |
Chief Executive Officer |
|
2022-07-31 |
4 |
D |
$3.40 |
$9,819 |
D/D |
(2,888) |
1,370,206 |
|
- |
|
Vasquez Christian |
See Remarks |
|
2022-07-31 |
4 |
D |
$3.40 |
$660 |
D/D |
(194) |
74,137 |
|
- |
|
Sievers Eric |
Chief Medical Officer |
|
2022-07-31 |
4 |
D |
$3.40 |
$1,884 |
D/D |
(554) |
86,727 |
|
- |
|
Waldron Richard A |
Chief Financial Officer |
|
2022-07-31 |
4 |
D |
$3.40 |
$3,298 |
D/D |
(970) |
126,624 |
|
- |
|
Smith Scott Andrew |
President |
|
2022-07-31 |
4 |
D |
$3.40 |
$6,089 |
D/D |
(1,791) |
329,835 |
|
- |
|
135 Records found
|
|
Page 2 of 6 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|